NABRIVA THERAPEUTICSCS PLC
NABRIVA THERAPEUTICSCS PLC
Share · IE00BYQMW233 · NBRV (XNAS)
Overview Financial Indicators
No Price
n/a

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
- - - - 0,00 % 0,00 % -99,68 %

Company Profile for NABRIVA THERAPEUTICSCS PLC Share

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Company Data

Name NABRIVA THERAPEUTICSCS PLC
Company Nabriva Therapeutics plc
Symbol NBRV
Website https://www.nabriva.com
Primary Exchange XNAS NASDAQ
ISIN IE00BYQMW233
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Dr. Colin Broom M.D.
Country Ireland
Currency USD
Employees 0,0 T
Address 25-28 North Wall Quay, 1 Dublin
IPO Date 2017-06-23

Ticker Symbols

Name Symbol
NASDAQ NBRV

More Shares

Investors who NABRIVA THERAPEUTICSCS PLC hold also have the following shares in their portfolio:
NORDLB 22/27
NORDLB 22/27 Bond
STRATEC SE
STRATEC SE Share
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025